Skip to main content
. Author manuscript; available in PMC: 2009 Feb 9.
Published in final edited form as: J Cereb Blood Flow Metab. 2007 Jan 24;27(7):1387–1396. doi: 10.1038/sj.jcbfm.9600447

Figure 7.

Figure 7

Administration of either CB2agonist (O-3853 or O-1966) 1 h before MCAO attenuated leukocyte/endothelial interactions. (A) The CB2agonists decreased the number of leukocytes rolling on venules at 1 and 24 h after MCAO. (B) The CB2agonists decreased the number of leukocyte adhering to on venules 1 and 24 h after MCAO. (C) The CB2agonists had no effect on leukocyte rolling on arterioles 1 h after MCAO compared with the vehicle-treated group. Both agonists decreased the number of leukocytes rolling on arterioles at 24 h after MCAO. (D) The CB2agonist (O-1966) had no effect on leukocyte adhesion to arterioles before MCAO and 1 h after MCAO compared with the vehicle-treated group, whereas O-3853 decreased the number of leukocyte adhesion on arterioles at 1 h after MCAO. Both agonists decreased leukocyte adhesion to arterioles at 24 h after MCAO. There was no difference of baseline of leukocyte rolling and adhesion on venules and arterioles among the groups. (Data were represented as mean±s.e.m., n = 6 in each groups, *P < 0.05 versus vehicle.)